Vismodegib Suppresses TRAIL-mediated Liver Injury in a Mouse Model of Nonalcoholic Steatohepatitis

Open Access

Peer-reviewed

Research Article

Petra Hirsova,

Affiliations Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, United States of America, Department of Pharmacology, Faculty of Medicine in Hradec Kralove, Charles University in Prague, Hradec Kralove, Czech Republic
⨯
Samar H. Ibrahim,

Affiliation Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, United States of America
⨯
Steven F. Bronk,

Affiliation Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, United States of America
⨯
Hideo Yagita,

Affiliation Department of Immunology, School of Medicine, Juntendo University, Tokyo, Japan
⨯
Gregory J. Gores

* E-mail: gores.gregory@mayo.edu

Affiliation Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, United States of America
⨯

Reader Comments (0)

Diet
Is the Subject Area "Diet" applicable to this article?

Thanks for your feedback.
Hedgehog signaling
Is the Subject Area "Hedgehog signaling" applicable to this article?

Thanks for your feedback.
Hepatocytes
Is the Subject Area "Hepatocytes" applicable to this article?

Thanks for your feedback.
Apoptosis
Is the Subject Area "Apoptosis" applicable to this article?

Thanks for your feedback.
Fatty liver
Is the Subject Area "Fatty liver" applicable to this article?

Thanks for your feedback.
Mouse models
Is the Subject Area "Mouse models" applicable to this article?

Thanks for your feedback.
Macrophages
Is the Subject Area "Macrophages" applicable to this article?

Thanks for your feedback.
Gene expression
Is the Subject Area "Gene expression" applicable to this article?

Thanks for your feedback.